On September 1, 2020 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that President and CEO Athena Countouriotis, M.D., will participate in question and answer sessions at the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the Citi 15th Annual BioPharma Virtual Conference on Sept. 10 (Press release, Turning Point Therapeutics, SEP 1, 2020, View Source [SID1234564366]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Countouriotis’ session is scheduled to begin at 2:40 p.m. ET on Sept. 9 and at 5:10 p.m. ET on Sept. 10. Both sessions will be accessible via webcast through the Investors page of www.tptherapeutics.com.

On September 1, 2020 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), reported that it will present at several upcoming investor conferences (Press release, Cellectis, SEP 1, 2020, View Source [SID1234564307]). Webcast information when available will be posted in the Investor Relations section of the Company’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi Annual BioPharma Conference September 9, 2020 from 3:20 PM to 4:05 PM EDT

André Choulika, Chairman & CEO, to participate in a panel on Innovation in Cell Therapy.

Wells Fargo Healthcare Conference Boston September 10, 2020 from 8:00 AM to 8:30 AM EDT

André Choulika; Carrie Brownstein, CMO; Simon Harnest, VP, Corporate Strategy & Finance to provide a company presentation.

Baird’s 2020 Global Healthcare Conference September 10, 2020 at 3:10 PM EDT

Simon Harnest to participate in a firechat and a live Q&A.

Bank of America Healthcare Conference London September 17, 2020 from 4:55 AM to 5:45 AM EDT

André Choulika to provide a company presentation.

On September 1, 2020, Rexahn Pharmaceuticals, Inc. (the "Company") reported that entered into a Warrant Exchange Agreement (the "Agreement") with Anson Investments Master Fund LP ("Anson") (Filing, 8-K, Rexahn, SEP 1, 2020, View Source [SID1234564274]). The Company previously issued to Anson (a) a warrant to purchase 62,500 shares (on a post-reverse stock split basis) of its common stock, par value $.0001 per share (the "Common Stock") pursuant to the offering described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on September 14, 2016 (the "2016 Warrant"), (b) a warrant to purchase 44,192 shares (on a post-reverse stock split basis) of Common Stock pursuant to the offering described in the Company’s Current Report on Form 8-K filed with the SEC on June 7, 2017 (the "2017 Warrant"), (c) a warrant to purchase 160,257 shares (on a post-reverse stock split basis) of Common Stock pursuant to the offering described in the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2018 (the "2018 Warrant"), and (d) warrants to purchase an aggregate of 145,502 shares (on a post-reverse stock split basis) of Common Stock pursuant to the offering described in the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2019 (the "2019 Warrants" and together with the 2016 Warrant, the 2017 Warrant and the 2018 Warrant, the "Warrants"). Pursuant to the Agreement, on September 1, 2020, the Company issued to Anson an aggregate of 192,878 shares of Common Stock in exchange for the surrender and cancellation of the Warrants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 1, 2020 Tavanta Therapeutics, a specialty pharmaceutical company with global headquarters in the Philadelphia, Pennsylvania area, reported its reorganization from Druggability Technologies Holdings Ltd (Hungary) (Press release, Tavanta Therapeutics, SEP 1, 2020, View Source [SID1234564264]). Focused on long-term growth, Tavanta has established a leadership team with a long and successful track record in the development and commercialization of novel specialty drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Completing the reorganization of key operational areas of the Company and optimizing our portfolio for strong, sustained growth in the United States have been critical steps for Tavanta," said Chief Executive Officer of Tavanta Therapeutics, Lynne Powell. "We have established a diverse, high-performing leadership team. Each member has enormous breadth and depth of experience and together we look forward to bringing new therapeutic solutions to patients and building value for our stakeholders."

Tavanta Therapeutics has embraced a vibrant, values-based culture that centers on creativity and experience. The name "Tavanta" is a reference to the Company’s commitment to advancing therapeutics designed to improve the lives of patients who have unmet medical needs.

Tavanta uses strategic partnerships early in the drug candidate identification process through in-licensing of drug targets to complement its own internally developed pipeline. The Company also seeks collaborative relationships for the development and commercialization of certain clinical candidates and welcomes inquiries from interested parties.

About the Tavanta Therapeutics Technology Platforms
Tavanta Therapeutics takes a risk-balanced approach to discovery and product development, deploying in-house platforms both to enhance the clinical performance of established molecules and to synthesize novel small molecules and therapeutic peptides. The result is a business model designed to lower the risk associated with the early stages of drug development, aimed toward accelerating new drug candidates into the clinic to reach patients with unmet medical needs.

Tavanta has established two platforms to support the rapid screening, identification and design of drug products for clinical development: High Throughput (HT) Matrix Screening Platform, and the Peptide Conjugate Development (PCD) Platform. The proprietary HT Matrix Screening platform is a bottom-up approach to improving the pharmacokinetic properties of poorly soluble pharmaceuticals, leading to the enhancement of certain important product characteristics. The PCD Platform is an integration of in-vitro and pre-clinical in-vivo testing designed to screen, characterize and design new peptides and peptide conjugates.

At the point at which candidate therapeutics are identified, Tavanta uses established pathways to support focused clinical development and regulatory approval. In the United States, these include both the standard 505(b)(1) and the expedited 505(b)(2) new drug application.

On September 1, 2020 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") reported that its Chief Executive Officer, Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at five conferences in September 2020 (Press release, VolitionRX, SEP 1, 2020, https://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-conferences-in-september-2020-301121771.html [SID1234564263]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conferences, Mr. Reynolds and Dr. Powell will outline Volition’s business, clinical, regulatory and operational milestones, as well as the Company’s recently announced quarterly financial results.

Details of the conference presentations (all virtual) are as follows:

Conference: LD Micro 500 Virtual Conference
Presentation Date/Time: Tuesday, September 1, 2020, 9:00 am EDT
Registration Link: View Source

Conference: GCFF Virtual Conference – Investing in Innovation
Presentation Date/Time: Thursday, September 10, 2020, 12:00 pm EDT
Registration Link: View Source

Conference: Cantor Virtual Global Healthcare Conference
Presentation Date/Time: Tuesday, September 15, 2020, 8:00 am EDT
Registration Link: https://cantor-fitzgerald-global-healthcare-conference.events.issuerdirect.com/signup

Conference: Life Sciences Investor Forum
Presentation Date/Time: Thursday, September 17, 2020, 10:00 am EDT
Registration Link: https://bit.ly/30GjErk

Conference: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Presentation Date/Time: Monday, September 21, 2020, 10:50 am EDT
Registration Link: View Source summit.aspx

Participants joining any of the above-referenced conferences who would like to schedule a virtual 1-on-1 meeting with Volition management may do so by registering at the links above, or by contacting Scott Powell, Executive Vice President of Investor Relations, at [email protected].